Chief Financial Officer · ORAMED PHARMACEUTICALS INC. (ORMP)

Avraham Gabay

A named executive officer of ORAMED PHARMACEUTICALS in every fiscal year CompBrief holds from FY2019 to FY2020. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$191,418

Salary $130,554Bonus $15,591

FY2019: $115,491

4th of 4 named executive officers at Oramed Pharmaceuticals by FY2020 total.

4 named officers on file for ORAMED PHARMACEUTICALS, FY2020

Avraham Gabay’s pay file — $29

  • 2 fiscal years of pay, line by line
  • ORMP’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ORAMED PHARMACEUTICALS’s whole pay program stands against its peers

  • ORAMED PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ORMP→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed July 28, 2021 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Avraham Gabay’s full pay file as a PDF — free

More than this page: up to 10 years of Avraham’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Avraham Gabay compensation by year

ORAMED PHARMACEUTICALS Summary Compensation Table · all 2 fiscal years held
In US dollars, as ORAMED PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020
Salary$32,122$130,554
Bonus$0$15,591
Stock awards$0—
Option awards$73,928$0
Non-equity incentive$0—
Pension and deferred compensation$0—
All other$9,441$44,912
Total$115,491$191,418

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ORAMED PHARMACEUTICALS INC. DEF 14A filed July 28, 2021, accession 0001213900-21-039099, and prior-year filings.

How this page was built: the ORAMED PHARMACEUTICALS INC. filed document, accession 0001213900-21-039099. Every figure is read from that document and cited to the page and table it appears in. Filed July 28, 2021.

$115K
$191K
FY19
FY20
SalaryBonusOption awardsAll other

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
Option27,750—$3.55

Per the Outstanding Equity Awards at Fiscal Year-End table in ORAMED PHARMACEUTICALS INC.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

16 Form 4 lines since the FY2020 proxy (filed July 28, 2021)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-11-12Grant or award—242,000—1,460,076
2026-11-12Grant or award—357,000—1,218,076
2026-10-01Sale10b5-120,000$4.51861,076
2026-09-24Grant or award—209,291—881,076
2026-07-01Sale—73,360$4.51671,785
2026-03-17Grant or award—95,889$0.00745,145
2026-01-22Exercise or conversion—19,000$0.00649,256
2026-01-22Exercise or conversion derivative—19,000$0.000

The 8 most recent of 16 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

ORAMED PHARMACEUTICALS’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Nadav KidronPresident, Chief Executive Officer and director (7)$1,767,851
Miriam KidronChief Scientific Officer and director (8)$688,700
Joshua HexterChief Operating & Business Officer (10)$608,833
Avraham Gabay · this pageChief Financial Officer$191,418

The full ORAMED PHARMACEUTICALS compensation record

free company brief

This page is one person within ORAMED PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the ORAMED PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ORAMED PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Avraham Gabay's compensation dossier · One-time report. No refunds.